The combination of microfluidic technology and surface-enhanced Raman spectroscopy (SERS) has the advantages of being label-free, fingerprint spectroscopy, and high sensitivity, which giving the combination great potential for rapid trace-level biological and environmental analysis. In this review, we summarized the recent progress in these two fields, e.g., microfluidics and SERS, including the basic strategies of a simple and versatile microfluidic-SERS detection system and its wide-ranging applications. Moreover, we listed the main challenges and future directions of the microfluidic-SERS systems; proposed on-chip applications beyond SERS; developed a more efficient, more sensitive, and more convenient microfluidic-SERS system; and formed a more complete on-site real-time detection technology.

A microfluidic droplet platform based on flow resistance has been designed to generate, capture and analyze a single cell. In this device, a single cell was encapsulated in micro-droplet form and positioned precisely in arrays of sloped channels on a polydimethylsiloxane–glass chip. The droplets were formed at the ‘T-junction’ and trapped by the ‘main–bypass’ construction. The single cell capture efficiency was up to 60%. Besides, the device caused no harm to living cells as the microdroplet formed here provided a relatively stable micro-environment. The device had the advantages of reagent economy, passive driving, and minimal cell damage, making it a powerful tool for single-cell analysis.

Bladder cancer diagnosis is made by microfluidic chip based-on impedance analysis.

Cisplatin‐containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient‐derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (n = 8) demonstrated a high level of correlation with the PDX (n = 2) and clinical response in patients (n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.